Management of Psychosis in Lewy Body Dementia

Treatment Approach

Patients who experience clinically meaningful reduction in neuropsychiatric symptoms with ChEIs should continue treatment even if there is evidence of cognitive and functional decline, as recommended by the Alzheimer's Association 1
ChEIs should not be discontinued in individuals who currently have clinically meaningful psychotic symptoms, agitation, or aggression until these symptoms have stabilized, according to the Alzheimer's Association 1
Non-pharmacological approaches should be implemented concurrently with pharmacological interventions, and treatment effectiveness should be regularly assessed using quantitative measures, as suggested by the American Geriatrics Society 2
Patients should be monitored closely for adverse effects, especially worsening parkinsonism or cognition, and regularly assess treatment effectiveness, as recommended by the American Academy of Neurology 3

Non-pharmacological interventions should always be assessed and implemented alongside medication management, including evaluating the patient's environment and social interactions that may trigger psychotic symptoms, as recommended by the American Psychiatric Association 2
Structured activities, calming measures, and support for family and caregivers should be implemented to help manage psychotic symptoms, as suggested by the National Institute on Aging 2

Treatment effectiveness should be regularly assessed using quantitative measures of psychosis, and patients should be monitored for cognitive worsening with any antipsychotic medication, as recommended by the American Academy of Neurology 2
If no clinically significant response after adequate trial, medication should be gradually discontinued, as suggested by the American Geriatrics Society 2